Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Common Equity: 2018-2019

Historic Common Equity for DiaMedica Therapeutics (DMAC) over the last 2 years, with Sep 2019 value amounting to $9.7 million.

  • DiaMedica Therapeutics' Common Equity rose 136.01% to $9.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was $9.7 million, marking a year-over-year increase of 136.01%. This contributed to the annual value of $17.0 million for FY2018, which is N/A change from last year.
  • Per DiaMedica Therapeutics' latest filing, its Common Equity stood at $9.7 million for Q3 2019, which was down 17.11% from $11.7 million recorded in Q2 2019.
  • DiaMedica Therapeutics' Common Equity's 5-year high stood at $17.0 million during Q4 2018, with a 5-year trough of $4.1 million in Q3 2018.
  • Over the past 2 years, DiaMedica Therapeutics' median Common Equity value was $9.7 million (recorded in 2019), while the average stood at $9.8 million.
  • Data for DiaMedica Therapeutics' Common Equity shows a peak YoY spiked of 136.01% (in 2019) over the last 5 years.
  • Quarterly analysis of 2 years shows DiaMedica Therapeutics' Common Equity stood at $17.0 million in 2018, then spiked by 136.01% to $9.7 million in 2019.
  • Its Common Equity stands at $9.7 million for Q3 2019, versus $11.7 million for Q2 2019 and $13.9 million for Q1 2019.